Canada markets closed

Small Pharma Inc. (DMTTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0939+0.0039 (+4.33%)
At close: 03:51PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.0900
Open0.0940
BidN/A x N/A
AskN/A x N/A
Day's Range0.0910 - 0.0990
52 Week Range0.0550 - 0.3328
Volume180,784
Avg. Volume96,875
Market Cap30.195M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0550
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue

    New United States patents will provide further support for the Company’s proprietary position in a key jurisdiction United States grants will bring the Company’s total to 16 granted patents and over 90 applications pending LONDON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces an update to its intellectua

  • Baystreet

    Stocks in play: Small Pharma Inc.

    Announces that SPL026, intravenous N,N-Dimethyltryptamine, with supportive therapy for the treatment ...

  • GlobeNewswire

    Small Pharma Reports Fiscal Third Quarter 2023 Highlights

    Positive top-line results from Phase IIa trial of SPL026 in Major Depressive Disorder New SPL026 trials underway and screening commenced in the first in-human study of SPL028 LONDON, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, has today published its financial results for the three and nine months ended November 30, 2